Top Markets
Coin of the day
WayPoint Biomedical Holdings, Inc. WayPoint Biomedical Holdings, Inc.

WayPoint Biomedical Holdings, Inc.

WYPH
Rangering i aksjer #41548
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary,... WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests for cocaine and marijuana detection. The company also develops and commercializes test kits for detection against possible explosive devices, biowarfare/bioterrorism agents, and the detection of weapons of mass destruction. In addition, it provides Frontline Explosive Test Kit for the detection of explosive residues. The company offers its products to the over-the-counter diagnostic self-testing, the diagnostic point of care, and the homeland security and defense markets. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California.
Aksjekurs
$0.0005
Sist synkronisert: 2026-08-12
Markedsverdi
$16.62K
Endring (1 dag)
-64.29%
Endring (1 år)
400.00%
Land
US
Handel WayPoint Biomedical Holdings, Inc. (WYPH)

Kategori

Inntekter for WayPoint Biomedical Holdings, Inc. (WYPH)
Inntekter i 2026 TTM: 0
Ifølge WayPoint Biomedical Holdings, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for WayPoint Biomedical Holdings, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$2.51B -
US
- -
CA
$1.91B -
US
$1.33B -
AU
$477.66M -
US